trial · primary record
ASC30 tablets
T2DM (Type 2 Diabetes Mellitus)
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2026-08-10 |
| Primary endpoint | Mean change from baseline in HbA1c up to 12 weeks in the treatment group compared with the placebo group |
| Registry ID | NCT07321678 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:05.747Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07321678
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.